{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:16:17Z","timestamp":1792610177770,"version":"4.5.0"},"reference-count":15,"publisher":"Centers for Disease Control and Prevention (CDC)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Emerg. Infect. Dis."],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.3201\/eid2703.202359","type":"journal-article","created":{"date-parts":[[2021,2,23]],"date-time":"2021-02-23T03:48:01Z","timestamp":1614052081000},"page":"944-948","source":"Crossref","is-referenced-by-count":24,"title":["Bedaquiline as Treatment for Disseminated Nontuberculous <i>Mycobacteria<\/i> Infection in 2 Patients Co-Infected with HIV"],"prefix":"10.3201","volume":"27","author":[{"given":"Eliza","family":"Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Morris-Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1822","reference":[{"key":"key-10.3201\/eid2703.202359-202102212242-R1","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1097\/00000441-200101000-00008","article-title":"Nontuberculous mycobacteria.","volume":"321","author":"Holland","year":"2001","journal-title":"Am J Med Sci"},{"key":"key-10.3201\/eid2703.202359-202102212242-R2","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria.","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"key-10.3201\/eid2703.202359-202102212242-R3","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/ijmy.ijmy_153_18","article-title":"Antimycobacterial strategies to evade antimicrobial resistance in the nontuberculous mycobacteria.","volume":"8","author":"Millar","year":"2019","journal-title":"Int J Mycobacteriol"},{"key":"key-10.3201\/eid2703.202359-202102212242-R4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug- and extensively drug-resistant tuberculosis.","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"key-10.3201\/eid2703.202359-202102212242-R5","unstructured":"M24Ed3 susceptibility testing of mycobacteria, Nocardia spp., and other aerobic Actinomycetes, 3rd ed. Wayne (PA): Clinical and Laboratory Standards Institute [cited 2020 Nov 6]. https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m24"},{"key":"key-10.3201\/eid2703.202359-202102212242-R6","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.027","article-title":"Minimum inhibitory concentration distributions for Mycobacterium avium complex-towards evidence-based susceptibility breakpoints.","volume":"55","author":"Sch\u00f6n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"key-10.3201\/eid2703.202359-202102212242-R7","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1086\/378807","article-title":"A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome.","volume":"37","author":"Benson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key-10.3201\/eid2703.202359-202102212242-R8","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1128\/AAC.02864-15","article-title":"Tigecycline potentiates clarithromycin activity against Mycobacterium avium in vitro.","volume":"60","author":"Bax","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.202359-202102212242-R9","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline.","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"key":"key-10.3201\/eid2703.202359-202102212242-R10","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1099\/jmm.0.000537","article-title":"In vitro activity of bedaquiline against rapidly growing nontuberculous mycobacteria.","volume":"66","author":"Aguilar-Ayala","year":"2017","journal-title":"J Med Microbiol"},{"key":"key-10.3201\/eid2703.202359-202102212242-R11","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1099\/jmm.0.001025","article-title":"In vitro activity of bedaquiline against slow-growing nontuberculous mycobacteria.","volume":"68","author":"Martin","year":"2019","journal-title":"J Med Microbiol"},{"key":"key-10.3201\/eid2703.202359-202102212242-R12","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1093\/jac\/dkw426","article-title":"Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.","volume":"72","author":"Cholo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"key-10.3201\/eid2703.202359-202102212242-R13","doi-asserted-by":"publisher","first-page":"4927","DOI":"10.1128\/AAC.00689-09","article-title":"ATP synthase inhibition of Mycobacterium avium is not bactericidal.","volume":"53","author":"Lounis","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.3201\/eid2703.202359-202102212242-R14","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1128\/JCM.02087-16","article-title":"Emergence of mmpT5 variants during bedaquiline treatment of Mycobacterium intracellulare lung disease.","volume":"55","author":"Alexander","year":"2017","journal-title":"J Clin Microbiol"},{"key":"key-10.3201\/eid2703.202359-202102212242-R15","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1093\/jac\/dky526","article-title":"A bedaquiline\/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.","volume":"74","author":"Ruth","year":"2019","journal-title":"J Antimicrob Chemother"}],"container-title":["Emerging Infectious Diseases"],"original-title":[],"link":[{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/27\/3\/20-2359_article","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,30]],"date-time":"2024-11-30T17:50:35Z","timestamp":1732989035000},"score":1,"resource":{"primary":{"URL":"https:\/\/wwwnc.cdc.gov\/eid\/article\/27\/3\/20-2359_article.htm"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"URL":"https:\/\/doi.org\/10.3201\/eid2703.202359","relation":{},"ISSN":["1080-6040","1080-6059"],"issn-type":[{"value":"1080-6040","type":"print"},{"value":"1080-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3]]}}}